RT journal article
T1 Invasive Fusariosis in Nonneutropenic Patients, Spain, 2000-2015
A1 Pérez-Nadales, Elena
A1 Alastruey-Izquierdo, Ana
A1 Linares-Sicilia, María José
A1 Soto-Debrán, Juan Carlos
A1 Abdala, Edson
A1 García-Rodríguez, Julio
A1 Montejo, Miguel
A1 Muñoz, Patricia
A1 Salavert Lletí, Miguel
A1 Rezusta, Antonio
A1 Ruiz Pérez de Pipaón, Maite
A1 Yáñez, Lucrecia
A1 Merino, Esperanza
A1 Campos-Herrero, María Isolina
A1 Costa-Mateo, José María
A1 Fortún, Jesús
A1 García-Lozano, Tomás
A1 Garcia-Vidal, Carolina
A1 Fernández-Ruiz, Mario
A1 Sánchez-Reus, Ferrán
A1 Castro-Méndez, Carmen
A1 Guerrero Lozano, Inmaculada
A1 Soler-Palacín, Pere
A1 Aguado, José María
A1 Martínez-Martínez, Luis
A1 Torre-Cisneros, Julian
A1 Nucci, Marcio
A1 Spanish Fusariosis Study Group
A2 BiomedicinaBiotecnología y Salud Pública
AB Invasive fusariosis (IF) is associated with severe neutropenia in patients with concurrent hematologic conditions. We conducted a retrospective observational study to characterize the epidemiology of IF in 18 Spanish hospitals during 2000-2015. In that time, the frequency of IF in nonneutropenic patients increased from 0.08 cases per 100,000 admissions in 2000-2009 to 0.22 cases per 100,000 admissions in 2010-2015. Nonneutropenic IF patients often had nonhematologic conditions, such as chronic cardiac or lung disease, rheumatoid arthritis, history of solid organ transplantation, or localized fusariosis. The 90-day death rate among nonneutropenic patients (28.6%) and patients with resolved neutropenia (38.1%) was similar. However, the death rate among patients with persistent neutropenia (91.3%) was significantly higher. We used a multivariate Cox regression analysis to characterize risk factors for death: persistent neutropenia was the only risk factor for death, regardless of antifungal therapy.
PB CENTERS DISEASE CONTROL & PREVENTION
SN 1080-6040
YR 2021
FD 2021-01
LK http://hdl.handle.net/10498/24512
UL http://hdl.handle.net/10498/24512
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 09-may-2026